ORNAV Orion Oyj
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. It offers pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Quetiapine products for antipsychotic; Trexan for rheumatoid arthritis and cancer; Easyhaler product portfolio for asthma and COPD; and Dexdor, Precedex, and Dexmedetomidine products for human use. The company also provides Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, it offers veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells drugs and products manufactured by other companies. Additionally, the company provides self-care products, including non-prescription medicines, cosmetics, dietary supplements, vitamins, and skincare products. It also offers its products online. The company has a licensing agreement with Tenax Therapeutics, Inc. to develop oral levosimendan (TNX-103) for pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF); and Bayer for the development and commercialisation of darolutamide Nubeqa. Orion Oyj was founded in 1917 and is headquartered in Espo, Finland.…
Industry Peers
Drug Manufacturers - GeneralKey Statistics
About Orion (HEL: ORNAV)
›
Orion (HEL: ORNAV) is listed on Nasdaq Helsinki, where its shares trade in EUR. It belongs to the Drug Manufacturers - General industry, part of the Healthcare sector, and reports about 4,215 employees.
The shares were at 101.00 EUR on 19 November 2026, up 77.1% over 52 weeks. Its 52-week range is 58.00 EUR to 103.80 EUR: the price is 2.7% below the high and 74.1% above the low.
At a market capitalisation of 14.16B EUR, it trades at 21.6 times trailing earnings. The median trailing P/E of its 19 largest Drug Manufacturers - General peers is 26.0, a discount of 17% for ORNAV. It pays a dividend yielding 1.78% (it pays out 37% of its earnings), against a median of 2.43% among the dividend payers in that peer group.
Orion reports return on equity of 38.9%, an operating margin of 38.1% and revenue up 28.1% year over year.
It holds more cash than debt, a net cash position of 18.80M EUR. Its Piotroski F-score is 6 out of 9, an average reading of its financial health.